JP2024521430A5 - - Google Patents
Info
- Publication number
- JP2024521430A5 JP2024521430A5 JP2023575935A JP2023575935A JP2024521430A5 JP 2024521430 A5 JP2024521430 A5 JP 2024521430A5 JP 2023575935 A JP2023575935 A JP 2023575935A JP 2023575935 A JP2023575935 A JP 2023575935A JP 2024521430 A5 JP2024521430 A5 JP 2024521430A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- composition
- prodrug
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208885P | 2021-06-09 | 2021-06-09 | |
| US63/208,885 | 2021-06-09 | ||
| PCT/US2022/032783 WO2022261287A1 (en) | 2021-06-09 | 2022-06-09 | Methods of treating nerve agent-induced seizures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521430A JP2024521430A (ja) | 2024-05-31 |
| JP2024521430A5 true JP2024521430A5 (enExample) | 2025-06-13 |
Family
ID=84425551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575935A Pending JP2024521430A (ja) | 2021-06-09 | 2022-06-09 | 神経剤誘発性発作を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277696A1 (enExample) |
| EP (1) | EP4352047A4 (enExample) |
| JP (1) | JP2024521430A (enExample) |
| KR (1) | KR20240022544A (enExample) |
| CN (1) | CN117836284A (enExample) |
| AU (1) | AU2022291138A1 (enExample) |
| CA (1) | CA3222575A1 (enExample) |
| IL (1) | IL309097A (enExample) |
| MX (1) | MX2023014418A (enExample) |
| WO (1) | WO2022261287A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1511741B1 (en) * | 2002-04-26 | 2012-12-26 | Eli Lilly And Company | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics |
| US11045462B2 (en) * | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
-
2022
- 2022-06-09 KR KR1020247000572A patent/KR20240022544A/ko active Pending
- 2022-06-09 CN CN202280052288.XA patent/CN117836284A/zh active Pending
- 2022-06-09 US US18/566,735 patent/US20240277696A1/en active Pending
- 2022-06-09 MX MX2023014418A patent/MX2023014418A/es unknown
- 2022-06-09 IL IL309097A patent/IL309097A/en unknown
- 2022-06-09 JP JP2023575935A patent/JP2024521430A/ja active Pending
- 2022-06-09 EP EP22821009.2A patent/EP4352047A4/en active Pending
- 2022-06-09 AU AU2022291138A patent/AU2022291138A1/en active Pending
- 2022-06-09 CA CA3222575A patent/CA3222575A1/en active Pending
- 2022-06-09 WO PCT/US2022/032783 patent/WO2022261287A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iftinca et al. | TRPV1-Targeted Drugs in Development for Human Pain Conditions: M. Iftinca et al. | |
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| Golembiewski et al. | Prevention and treatment of postoperative nausea and vomiting | |
| Schwarzkopf et al. | Midazolam pretreatment reduces etomidate-induced myoclonic movements | |
| JP7440092B2 (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| BR112020003025A2 (pt) | métodos de tratamento de osteoartrite com gel transdérmico de canabidiol | |
| Thakur et al. | Treating herpes zoster and postherpetic neuralgia: An evidence-based approach | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| JP2017515847A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| Safavi et al. | Low dose intravenous midazolam for prevention of ponv, in lower abdominal surgery | |
| Keppel Hesselink | Bimoclomol and arimoclomol: HSP-co-inducers for the treatment of protein misfolding disorders, neuropathy and neuropathic pain | |
| JP2024521430A5 (enExample) | ||
| JP2025517509A5 (enExample) | ||
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| JP2014530249A5 (enExample) | ||
| Cantisani et al. | New patents on topical anesthetics | |
| Seale et al. | Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis | |
| RU2023135655A (ru) | Способы лечения судорожных припадков, индуцированных нервно-паралитическим средством | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| Iosifescu | Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge | |
| JP2024502466A5 (enExample) | ||
| Lomia et al. | Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine |